Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported revenue was INR 1.02 million compared to INR 175.54 million a year ago. Net loss was INR 46.84 million compared to INR 3.29 million a year ago. Basic loss per share from continuing operations was INR 1.08 compared to INR 0.08 a year ago. Diluted loss per share from continuing operations was INR 1.08 compared to INR 0.08 a year ago.
For the nine months, sales was INR 369.59 million. Revenue was INR 375.24 million. Net loss was INR 127.63 million.